Haas Jason sold $2.1M of LGND
Haas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.
How this was made
The 30-second read
Why it matters
Traders may monitor insider activity as a sentiment input, but this filing alone does not change Ligand’s fundamentals or near-term expectations.
Market read
A director open-market sale of about $2.09M is disclosed, which can slightly pressure sentiment but lacks fundamental catalysts.
What to watch
No 10b5-1 plan is cited, but the filing does not disclose intent, diversification needs, or whether other insiders are selling/buying concurrently.
Background
The article is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals, reported via SEC EDGAR.
Ticker impact
SEC Form 4 shows director Jason Haas sold 7,138 shares of Ligand Pharmaceuticals at $292.8078 on 2026-08-12.
Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.
The transaction is a director sale with no 10b5-1 plan stated and no accompanying company news, so it is typically viewed as low-signal unless part of a broader pattern.
Market effects
Minimal; this is company-specific insider activity with no disclosed sector-wide regulatory or clinical development.
None indicated.
None indicated.
Counterpoint
The sale may be routine liquidity or tax-related, especially without any stated link to company performance.
Key entities
- issuerLGND
Ligand Pharmaceuticals Inc., the company whose director insider sale is disclosed.
- insiderHaas Jason
Director of Ligand Pharmaceuticals who sold shares in an open-market transaction.
